Samuel A Jacobs

Summary

Affiliation: University of Pittsburgh
Country: USA

Publications

  1. doi request reprint Concurrent bevacizumab with a sequential regimen of doxorubicin and cyclophosphamide followed by docetaxel and capecitabine as neoadjuvant therapy for HER2- locally advanced breast cancer: a phase II trial of the NSABP Foundation Research Group
    Priya Rastogi
    National Surgical Adjuvant Breast and Bowel Project, Four Allegheny Center, Pittsburgh, PA 15212, USA
    Clin Breast Cancer 11:228-34. 2011
  2. pmc Yttrium ibritumomab tiuxetan in the treatment of non-Hodgkin's lymphoma: current status and future prospects
    Samuel A Jacobs
    University of Pittsburgh School of Medicine, 5150 Centre Avenue, Pittsburgh, PA, USA
    Biologics 1:215-27. 2007
  3. ncbi request reprint The expanding role of rituximab and radioimmunotherapy in the treatment of B-cell lymphomas
    Samuel A Jacobs
    University of Pittsburgh School of Medicine, 5150 Centre Avenue, Pittsburgh, PA 15232, USA
    Expert Opin Biol Ther 7:1749-62. 2007
  4. doi request reprint Phase II trial of short-course CHOP-R followed by 90Y-ibritumomab tiuxetan and extended rituximab in previously untreated follicular lymphoma
    Samuel A Jacobs
    Department of Medicine, University of Pittsburgh Medical Center Cancer Centers, Pittsburgh, Pennsylvania 15232, USA
    Clin Cancer Res 14:7088-94. 2008
  5. doi request reprint Radioisotopic localization of (90)Yttrium-ibritumomab tiuxetan in patients with CD20+ non-Hodgkin's lymphoma
    S A Jacobs
    University of Pittsburgh Medical Center, University of Pittsburgh Cancer Institute and UPMC Cancer Centers, PA 15232, USA
    Mol Imaging Biol 11:39-45. 2009
  6. ncbi request reprint Monoclonal antibody therapy of leukaemias and lymphomas
    Samuel A Jacobs
    University of Pittsburgh School of Medicine, 5150 Center Avenue, Suite 510, Pittsburgh, PA 15232, USA
    Expert Opin Biol Ther 5:1225-43. 2005
  7. ncbi request reprint Durable remission of HIV-negative, Kaposi's sarcoma herpes virus-associated multicentric Castleman disease in patient with rheumatoid arthritis treated with methotrexate
    Samuel A Jacobs
    University of Pittsburgh Cancer Institute, Pittsburgh 15232, USA
    Clin Rheumatol 26:1148-50. 2007
  8. ncbi request reprint Focal radiation fibrosis after radioimmunotherapy for follicular non-Hodgkin lymphoma
    Nicholas A DeMonaco
    Department of Hematology Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15232, USA
    Clin Lymphoma Myeloma 7:369-72. 2007
  9. ncbi request reprint Full-dose 90Y ibritumomab tiuxetan therapy is safe in patients with prior myeloablative chemotherapy
    Samuel A Jacobs
    University of Pittsburgh Cancer Institute, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania 15232, USA
    Clin Cancer Res 11:7146s-7150s. 2005
  10. ncbi request reprint Anaphylaxis after administration of ibritumomab tiuxetan for follicular non-hodgkin lymphoma
    Rachel Jankowitz
    UPMC Cancer Centers, UPMC Cancer Pavilion, Pittsburgh, Pennsylvania, USA
    Clin Nucl Med 33:94-6. 2008

Collaborators

Detail Information

Publications18

  1. doi request reprint Concurrent bevacizumab with a sequential regimen of doxorubicin and cyclophosphamide followed by docetaxel and capecitabine as neoadjuvant therapy for HER2- locally advanced breast cancer: a phase II trial of the NSABP Foundation Research Group
    Priya Rastogi
    National Surgical Adjuvant Breast and Bowel Project, Four Allegheny Center, Pittsburgh, PA 15212, USA
    Clin Breast Cancer 11:228-34. 2011
    ..The purpose of this trial was to determine the activity and safety profile of neoadjuvant bevacizumab with chemotherapy in women with locally advanced breast cancer (LABC)...
  2. pmc Yttrium ibritumomab tiuxetan in the treatment of non-Hodgkin's lymphoma: current status and future prospects
    Samuel A Jacobs
    University of Pittsburgh School of Medicine, 5150 Centre Avenue, Pittsburgh, PA, USA
    Biologics 1:215-27. 2007
    ....
  3. ncbi request reprint The expanding role of rituximab and radioimmunotherapy in the treatment of B-cell lymphomas
    Samuel A Jacobs
    University of Pittsburgh School of Medicine, 5150 Centre Avenue, Pittsburgh, PA 15232, USA
    Expert Opin Biol Ther 7:1749-62. 2007
    ..As mechanisms of action/resistance to monoclonal antibody therapy are better understood, approaches to predicting response and optimizing combination therapy to overcoming primary and acquired resistance may be developed...
  4. doi request reprint Phase II trial of short-course CHOP-R followed by 90Y-ibritumomab tiuxetan and extended rituximab in previously untreated follicular lymphoma
    Samuel A Jacobs
    Department of Medicine, University of Pittsburgh Medical Center Cancer Centers, Pittsburgh, Pennsylvania 15232, USA
    Clin Cancer Res 14:7088-94. 2008
    ....
  5. doi request reprint Radioisotopic localization of (90)Yttrium-ibritumomab tiuxetan in patients with CD20+ non-Hodgkin's lymphoma
    S A Jacobs
    University of Pittsburgh Medical Center, University of Pittsburgh Cancer Institute and UPMC Cancer Centers, PA 15232, USA
    Mol Imaging Biol 11:39-45. 2009
    ....
  6. ncbi request reprint Monoclonal antibody therapy of leukaemias and lymphomas
    Samuel A Jacobs
    University of Pittsburgh School of Medicine, 5150 Center Avenue, Suite 510, Pittsburgh, PA 15232, USA
    Expert Opin Biol Ther 5:1225-43. 2005
    ..This paper reviews rituximab, alemtuzumab and gemtuzumab ozogamicin as monoclonal antibody therapies for leukaemias and lymphomas...
  7. ncbi request reprint Durable remission of HIV-negative, Kaposi's sarcoma herpes virus-associated multicentric Castleman disease in patient with rheumatoid arthritis treated with methotrexate
    Samuel A Jacobs
    University of Pittsburgh Cancer Institute, Pittsburgh 15232, USA
    Clin Rheumatol 26:1148-50. 2007
    ..As such, we suggest that the dramatic improvement in this patient's disease is due to the immunomodulatory properties of MTX...
  8. ncbi request reprint Focal radiation fibrosis after radioimmunotherapy for follicular non-Hodgkin lymphoma
    Nicholas A DeMonaco
    Department of Hematology Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15232, USA
    Clin Lymphoma Myeloma 7:369-72. 2007
    ..This is the first case in which radiation-induced radiographic changes are reported after RIT for lymphoma...
  9. ncbi request reprint Full-dose 90Y ibritumomab tiuxetan therapy is safe in patients with prior myeloablative chemotherapy
    Samuel A Jacobs
    University of Pittsburgh Cancer Institute, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania 15232, USA
    Clin Cancer Res 11:7146s-7150s. 2005
    ..We treated eight patients with 90Y ibritumomab tiuxetan who had prior autologous stem cell transplant, but met all other treatment criteria...
  10. ncbi request reprint Anaphylaxis after administration of ibritumomab tiuxetan for follicular non-hodgkin lymphoma
    Rachel Jankowitz
    UPMC Cancer Centers, UPMC Cancer Pavilion, Pittsburgh, Pennsylvania, USA
    Clin Nucl Med 33:94-6. 2008
    ..After successful resuscitation, a human antimouse antibody (HAMA) level was found to be elevated, 618 ng/mL (reference 0-188 ng/mL)...
  11. ncbi request reprint Serum sickness in a patient with follicular lymphoma after rituximab and radioimmunotherapy with ibritumomab tiuxetan
    Nicholas A DeMonaco
    Oncology Hematology Associates, PA, Clinton, Maryland, USA
    Clin Nucl Med 32:933-4. 2007
    ..Despite anti-inflammatory therapies her symptoms persisted for 10 months before ultimate resolution. Her clinical course and literature are reviewed...
  12. ncbi request reprint A phase I/II study of trimetrexate and capecitabine in patients with advanced refractory colorectal cancer
    Khalid Matin
    Division of Hematology Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
    Am J Clin Oncol 28:439-44. 2005
    ..Because the optimum dose of this combination was unknown, we used a phase I/II design...
  13. ncbi request reprint Randomized trial of influenza vaccine with granulocyte-macrophage colony-stimulating factor or placebo in cancer patients
    Ramesh K Ramanathan
    University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA
    J Clin Oncol 20:4313-8. 2002
    ..To determine whether granulocyte-macrophage colony-stimulating factor (GM-CSF) would improve response to influenza vaccination in cancer patients...
  14. ncbi request reprint Phase I study of weekly (day 1 and 8) docetaxel in combination with capecitabine in patients with advanced solid malignancies
    Ramesh K Ramanathan
    Department of Medicine, Division of Hematology Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
    Cancer Chemother Pharmacol 55:354-60. 2005
    ..To improve the therapeutic index, we evaluated a weekly regimen of docetaxel in combination with capecitabine, and determined the maximum tolerated dose, toxicities and pharmacokinetics of this combination...
  15. ncbi request reprint Pemetrexed/oxaliplatin for first-line treatment of patients with advanced colorectal cancer: a phase II trial of the National Surgical Adjuvant Breast and Bowel Project Foundation Research Program
    James N Atkins
    National Surgical Adjuvant Breast and Bowel Project, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15212, USA
    Clin Colorectal Cancer 5:181-7. 2005
    ..In this study, these drugs were used in combination as first-line therapy in a group of patients with metastatic colorectal cancer...
  16. ncbi request reprint Indolent mantle cell lymphoma with nodal involvement and mutated immunoglobulin heavy chain genes
    Laurentia Nodit
    Department of Pathology, University of Pittsburgh School of Medicine, PA, USA
    Hum Pathol 34:1030-4. 2003
    ..The subtle but diagnostic lymph node biopsy in this case helps to further support that an indolent t(11;14) monoclonal lymphocytosis with mutated Ig genes can represent an MCL variant rather than chronic lymphocytic leukemia...
  17. ncbi request reprint A phase II clinical trial of ZD1839 (Iressa) in combination with docetaxel as first-line treatment in patients with advanced breast cancer
    Sheri K Dennison
    Walter Reed Army Medical Center, 6900 Georgia Ave NW, Washington, DC 20307, USA
    Invest New Drugs 25:545-51. 2007
    ..The combination of gefitinib and docetaxel is an active regimen in patients with previously untreated metastatic breast cancer, with a clinical benefit rate and toxicity profile in the range of that reported for docetaxel alone...
  18. ncbi request reprint A phase II study of topotecan in non-Hodgkin's lymphoma: an Ohio State University phase II research consortium study
    Eric H Kraut
    Ohio State University Medical Center and Arthur G James Cancer Hospital and Research Institute, Columbus, Ohio, USA
    Cancer Invest 20:174-9. 2002
    ..This multicenter phase II trial evaluated the efficacy and toxicity of the topoisomerase I inhibitor topotecan (TPT, 9-dimethylaminomethyl-10-hydroxycamptothecin) in patients with refractory or relapsing non-Hodgkin's lymphoma...